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Abstract
Embryo attachment and implantation is critical to successful reproduction of all eutherian
mammals, including humans; a better understanding of these processes could lead to improved
infertility treatments and novel contraceptive methods. Experience with assisted reproduction,
especially oocyte donation cycles, has established that despite the diverse set of hormones
produced by the ovary in a cycle-dependent fashion, the sequential actions of only two of them,
oestrogen and progesterone, are sufficient to prepare a highly receptive endometrium in humans.
Further investigation on the endometrial actions of these two hormones is currently providing
significant insight into the implantation process in women, strongly suggesting that an abnormal
response to progesterone underlies infertility in some patients.
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Introduction
A thorough understanding of the processes governing human embryo implantation would be
of significant benefit for the treatment of infertility and the development of novel
contraceptives. However, implantation processes remain poorly understood, largely due to
differences between humans and experimental animals and appropriate ethical, moral and
legal barriers to direct examination of implanting human embryos. Despite these barriers,
significant knowledge has been gained through experience with assisted reproduction
coupled with application of improving analytic techniques applied to human tissues and
non-human primate models.
Experience with donor oocyte IVF cycles has allowed profound clinical insights into the
regulation of human endometrial receptivity. Donor oocyte cycles achieve the highest
implantation rates of all assisted reproduction approaches (Sunderam et al. 2009), suggesting
that the hormonal preparation of the endometrium has been well optimized (van der Linden
et al. 2011). In donor oocyte cycles, the endometrium of the recipient is prepared by
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sequential treatment with oestrogen and progesterone, using protocols that prevent ovulation
and corpus luteum formation. Notably, these protocols work just as well in a woman without
ovaries. Thus, these two hormones, without any other ovarian or corpus luteum products, are
sufficient for excellent preparation of human endometrium to accept an implanting embryo.
Their primacy is further supported by the requirement of both hormones for pregnancy
initiation and early survival in all eutherian mammals, despite major species-specific
differences in ovarian and uterine anatomy and physiology. Given the critical and
fundamental role that oestrogen and progesterone play in establishment of receptivity, a
deep understanding of the action of these steroid hormones on the human endometrium will
allow clear insight into the mechanisms determining endometrial receptivity. This review
will attempt to summarize the current, albeit limited, understanding of oestrogen and
progesterone action in determination of endometrial receptivity.
Molecular biology of oestrogen and progesterone action
Both oestrogen and progesterone act through specific, high-affinity, low-capacity nuclear
receptors that function as ligand-activated transcription factors and chromatin modifiers to
directly regulate expression of a large number of genes (Cheung and Kraus 2010; Huang et
al. 2010). The products of steroid receptor-regulated genes can also act in a downstream,
autocrine, paracrine or endocrine fashion to regulate expression of additional genes. It is
important to recognize that some non-steroidal ligands can also bind the steroid receptors.
Examples of non-steroidal ligands which act through oestrogen receptors include
endogenous lipoxin A4 (LXA4), an eicosanoid produced in the endometrium (Russell et al.
2011), bisphenol A, an environmental compound (Li et al. 2012), and clomiphene citrate, a
pharmaceutical agent. Thus, nuclear steroid receptors are responsible for the so-called
‘classical’ actions of oestrogen and progesterone (Figure 1).
It is important to point out some significant simplifications made to improve readability in
Figure 1. For example, oestrogen receptors and progesterone receptors are bound to
chaperone proteins and are released from them after ligand binding. Chaperone binding may
regulate steroid receptor availability and access to the nucleus, and therefore function.
Another key feature of the classical actions of oestrogen and progesterone, not included in
Figure 1, is that there are multiple oestrogen receptor and progesterone receptor isoforms,
each having distinct actions on the genome. Differential expression of these isoforms in
different cell types and physiological states results in differential effects of the steroids.
There are two nuclear oestrogen receptors – oestrogen receptor α and oestrogen receptor β –
each derived from a distinct gene (ESR1 and ESR2, respectively). These genes have high
sequence homology, likely resulting from an ancient gene duplication event, since
homologous genes are seen in fish and amphibians as well as mammals (Katsu et al. 2008).
Although similar in structure, oestrogen receptors and have distinct effects in experimental
model organisms and distinct patterns of expression in human disease (Hewitt and Korach
2003). For example, overexpression of oestrogen receptor is observed in endometrioma
lesions due to hypomethylation of the promoter leading to a molecular cascade resulting in
inflammation and other pathophysiological changes (Bulun et al. 2010).
The progesterone receptors have at least two isoforms – progesterone receptor A and
progesterone receptor B. Unlike oestrogen receptors, the progesterone receptor isoforms are
derived from alternate transcription and translation start sites in a single gene (PGR; Ogle
2002; Jacobsen and Horwitz 2012). Progesterone receptor A and B are identical in structure
except that the progesterone receptor B isoform contains a 164-amino acid N-terminal
sequence, which is lacking in the progesterone receptor A isoform. The presence or absence
of the N-terminal extension appears to be responsible for the distinct differences in
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progesterone receptors A and B actions. Truncated isoforms – progesterone receptor C and
progesterone receptor M – that retain the progesterone-binding domain but lose the DNA-
binding domain have been described as a possible suppressor of progesterone receptors A
and B action, but their relevance in vivo is controversial (Wei et al. 1990; Samalecos and
Gellersen 2008; Taylor et al. 2009).
A further level of complexity is seen in the interaction between steroid receptors and co-
activators and co-repressors. These co-activators and repressors mediate the effects of the
nuclear receptors on gene transcription (Figure 1). The expression and activity of the co-
activators and co-repressors can be determined both developmentally and dynamically in the
adult, providing a further basis for the pleiotropic effects of steroid hormones. In this regard,
it is important to note that there are distinct mechanistic differences between mammalian
species in steroid hormone and co-activator expression. For example, oestrogen receptor
appears to be significantly more expressed in human endometrium as opposed to the mouse.
A more extreme example is the progesterone receptor B specific co-activator, MAGEA-11,
which is only present in primates and appears to play an important role in the human
endometrial response to progesterone (Su et al. 2012).
The effects of progesterone via its receptor also depend on other signals and transcription
factors. An indisputably critical action of progesterone on endometrial stroma is
decidualization. However, full decidualization requires signalling by both progesterone
receptor and cAMP (Kajihara et al. 2013). Interestingly, cAMP induces expression of many
transcription factors, including FOXO1, C/EBPb (CCAAT/enhancer-binding protein b),
STAT5 (signal transducers and activators of transcription 5) and HOXA11, all of which
directly interact with and modulate progesterone receptor (Kajihara et al. 2013). These
factors, including progesterone receptor, form multimeric complexes at promoters for genes
critical to a decidualized phenotype. Without this synergistic interaction between other
cellular signals and transcription factors, progesterone would not exert this important effect
on endometrial stroma. Emerging data suggesting that progesterone-driven decidualization
may act as a biosensor of embryo quality during early implantation is reviewed by Lucas in
this issue (Lucas, 2013).
Another simplification in Figure 1 is that steroid receptors dynamically interact with
chromatin in a manner regulated by chromatin remodelling, chaperones, the proteasome and
binding of other transcription factors (Grontved and Hager 2012). Oestrogen receptor and
progesterone receptor isoforms can only bind DNA if the chromatin structure is open
enough to allow access. The areas of open and closed chromatin in a particular cell type in a
particular physiological environment are yet another mechanism for tissue-specific actions
of oestrogen and progesterone.
In this context, it is important to note that epigenetic mechanisms and microRNA expression
may be important modifiers of progesterone action. Initial studies in humans have shown
epigenetic changes with cycle phase, including alterations in DNA methyltransferase and
histone-modifying enzyme expression (Guo 2012). Initial studies have also shown
significant cycle-regulated changes in microRNA through the cycle (Sha et al. 2011; Altmae
et al. 2013). The role of microRNA in both normal endometrium and in endometriosis are
discussed in the review by Hull and Nisenblat (2013, in this issue).
In addition to their direct, genomic effects, both oestrogen and progesterone also exert rapid,
‘non-classical’ effects on the cell via action at the plasma membrane, via nuclear receptors
interacting with other transcription factors or via less well-understood effects on mRNA
stability (Figure 2). Oestrogen can act through both membrane-associated oestrogen receptor
and a structurally unrelated, integral membrane, G-protein coupled oestrogen receptor,
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GPR30, to stimulate one or more cytoplasmic signalling cascades in response to oestrogen.
The effects of signalling via GPR30 in the endometrium are unclear, but there is a profound
cyclic regulation of this receptor (Plante et al. 2012).
The non-classical actions of progesterone are less-well understood, but no less complex. As
mentioned above, alternative transcription start sites in PGR may result in production of
progesterone receptor M or progesterone receptor C, although conflicting evidence exists
regarding their relevance in vivo. A separate family of membrane progesterone receptors,
mPRα (PAQR VII), mPRβ (PAQR VIII) and mPRγ (PAQR V) that are structurally
unrelated to the PGR gene, can also bind progesterone and are thought to activate G-protein
coupled signalling pathways (Zhu et al. 2003; Dressing et al. 2011). Significant controversy
exists regarding the structure and function of this molecular family. For example, the
predicted structure of PAQR family members shows eight transmembrane domains rather
than the seven seen in the G-protein coupled receptor family and there is no significant
sequence similarity to known G-protein coupled receptors (Moussatche et al. 2012).
Furthermore, the PAQR family shows sequence motifs more closely related to alkaline
ceramidases and may have similar enzymic activity (Moussatche et al. 2012). Thus, the
function of the PAQR family receptors remains to be firmly established and although
expression of the mRP family has been shown in the human endometrium, their role in
endometrial function remains unclear (Fernandes et al. 2005). Finally, a newly described
membrane channel/receptor on human spermatozoa, CatsPer, is capable of binding
progesterone (and other compounds released by the cumulus–oocyte complex) and causing
calcium influx (Brenker et al. 2012; Lishko et al. 2011). However, CatsPer expression
appears to be sperm specific and is, therefore, unlikely to play a role in the endometrium.
Endometrial receptivity to embryo implantation exists for a brief period of time and this
timing is driven by time of progesterone exposure, only after sufficient exposure to
oestrogen. Given this temporally specific process, it is not surprising that expression and
localization of steroid receptors and their co-regulators vary markedly in different menstrual
cycle phases (Table 1). In all eutherian mammals studied, oestrogen receptor disappears
from the endometrial epithelium at the time of embryo implantation (Donaghay and Lessey
2007). In the human endometrial epithelium, both oestrogen receptor and progesterone
receptor immunohistochemical staining diminish markedly during the midsecretory
implantation window (Lessey et al. 1988; Young and Lessey 2010). Further analysis of the
mid- and late proliferative phases shows that progesterone receptors A and B are easily
detected in both epithelial and stromal compartments of the human endometrium (Mote et
al. 2000; Wang et al. 1998). In the secretory-phase epithelium, progesterone receptor A
expression is virtually absent during the mid- and late secretory phases, while progesterone
receptor B expression is maintained at low concentrations through the mid-secretory phase
and falls to even lower concentrations by the late secretory phase. In the stroma,
progesterone receptor A expression is significantly higher than progesterone receptor B
throughout the cycle, although present in low abundance in the late secretory phase. Given
the absence or paucity of oestrogen receptor and progesterone receptors A and B in the mid-
to late secretory endometrial epithelium, it is likely that epithelial effects of oestrogen and
progesterone during these cycle phases results from oestrogen- or progesterone-induced
paracrine factors, produced in the stroma and acting on the epithelium, termed oestromedins
and progestomedins. Potential human endometrial oestromedins and progestomedins include
insulin-like growth factor 1 (Giudice et al. 1993), heparin-binding epidermal growth factor
(Leach et al. 1999; Young et al. 2002) and fibroblast growth factor 7 (Koji et al. 1994).
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Role of oestrogen in embryo implantation
While molecular studies of oestrogen and progesterone receptors provide the mechanistic
framework for understanding endometrial function, it is the physiological and clinical
studies that provide the most practical insight into implantation mechanisms. Oestrogen is
essential for endometrial proliferation, as repeatedly demonstrated in humans and
experimental animals lacking ovaries and those in whom oestrogen production or action has
been prevented.
The role for oestrogen in the secretory phase and in implantation is less clear. In mice,
oestrogen appears to be critical to support implantation and early pregnancy (Dey et al.
2004). Interestingly, the decidualized mouse endometrium appears to produce its own
oestradiol and does not require corpus luteum-derived oestrogens (Das et al. 2009). As far as
is known, there is no substantive data to support this pathway in human decidua.
There are, of course, many differences between human 28-day menstrual cycle and the
mouse 4-day oestrus cycle, including circulating oestradiol concentrations. Mouse peak
serum oestradiol concentrations in pro-oestrus are equal to or lower than typical
perimenstrual nadir concentrations in the human and 10–20 times lower than peak
preovulatory concentrations. However, oestrogen action in the human midsecretory phase
could possibly occur through other, non-steroidal oestrogen receptor agonists. An
eicosanoid, LXA4, was recently shown to bind oestrogen receptor and act as an agonist, and
the biosynthetic pathway for LXA4 appears to be present in the human endometrium
(Russell et al. 2011). Further work is needed, however, to determine any role that LXA4
might play in the human endometrium.
Studies in women without functional ovaries demonstrate that luteal oestrogen is not
necessary for normal day-25 morphology or normal changes in oestrogen receptor and
progesterone receptor immunolocalization (de Ziegler et al. 1992). Surprisingly no vaginal
spotting was noted in the subjects during the 10 days of progesterone treatment without any
oestrogen given. In another study employing oestrogen receptor antagonism with
clomiphene begun 2 days after LH surge in a spontaneous cycle and continued until biopsy
on day 13 resulted in consistently delayed histological maturation (Fritz et al. 1987). The
clomiphene antagonism study findings are echoed by experiments in the bonnet macaque; in
these studies, peri-implantation administration of aromatase inhibitor (fadrozole) or
oestrogen antagonist (tamoxifen) markedly decreased, but did not eliminate, conception. In
another primate study, this time in oophorectomized rhesus macaques, provision of
progesterone alone was able to support endometrial receptivity, early post-implantation
embryo development and normal pregnancy (Ghosh et al. 1994).
In order to better understand these apparently conflicting data, this study group analysed
gonadotrophin-releasing hormone downregulated cycles followed by oestrogen (at varying
doses) and progesterone replacement (Groll et al. 2009). Effects on endometrial histology
and immunohistochemical staining for integrin subunit β, osteopontin, oestrogen receptor
and progesterone receptors A and B were examined. These studies demonstrated no
difference in between groups not receiving oestradiol and those receiving physiological or
supraphysiological oestradiol.
It is striking that the oestrogen receptor inhibitor studies demonstrate a necessity for luteal-
phase oestrogen, while progesterone (with or without oestrogen) replacement studies show
no luteal-phase requirement. A possible explanation is that in studies where exogenous
progesterone is given, there is sufficient extra-ovarian conversion of progesterone to
oestrogen (via testosterone) to maintain endometrial function. The oestradiol antagonism
and aromatase inhibition studies might provide a more profound impact by blocking
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oestrogen action (even that derived in the endometrium). The data in the ovariectomized
rhesus macaque, however, remains remarkable, because systemic oestradiol concentrations
were measured and shown to be very low, even with administration of progesterone. Taken
together, the data suggest that the (human or non-human) primate endometrium appears to
function normally with very low concentrations of oestradiol.
Clinical data are also mixed. It is well known that use of gonadotrophin-releasing hormone
agonists or antagonists in non-donor IVF cycles results in a shortened luteal phase and
possibly other qualitative luteal defects. Thus, luteal support with progesterone and
sometimes oestrogen is given. Clinical outcomes are mixed demonstrating a benefit of luteal
oestrogen supplementation in IVF (Farhi et al. 2000; Lukaszuk et al. 2005) or no benefit
(Smitz et al. 1993; Lewin et al. 1994; Fatemi et al. 2007). The most recent systematic review
suggests no overall benefit (Fatemi et al. 2007). Given the experimental results in women
and monkeys with absent luteal function and the mixed evidence in clinical trials, any
possible clinical benefit of luteal oestrogen support in IVF must accrue only to a small
subset of patients.
Role of progesterone in embryo implantation
Progesterone is absolutely required for successful embryo implantation and pregnancy
maintenance. In fact, progesterone was discovered because of its effects on the endometrium
and early pregnancy survival (Allen and Doisey 1923; Allen and Corner 1929). The effects
of progesterone on the endometrium were confirmed in non-human primates (Zuckerman
1937), leading Georgeanna Seeger Jones to characterize patients with possible progesterone
deficiency leading to infertility (Jones 1949; Jones 1973). The concept that progesterone
insufficiency will cause infertility is logically irrefutable. Progesterone is necessary for
implantation and pregnancy survival and thus, at some lower threshold, there will be
insufficient progesterone for these functions. However, the methods of diagnosing
progesterone insufficiency (or sufficiency) and therefore its role in patients have been
controversial.
There are three major contributors to the uncertainty regarding the role of luteal-phase defect
in infertility. The first is that the corpus luteum releases progesterone in pulses, which are
rapidly cleared from the body, resulting in marked fluctuations of progesterone serum
concentrations (Filicori et al. 1984), changing as much as 6-fold within a few hours. The
rapidly fluctuating concentrations preclude using individual serum progesterone
measurements as a measurement of progesterone sufficiency. Secondly, there is no ‘gold
standard’ marker of endometrial receptivity to embryo implantation that would allow
evaluation of endometrial function outside of a conception cycle. Current progress in the
identification of markers of the receptive endometrium is discussed by Salamonsen et al.
(2013, in this issue). Thirdly, there are clear differences between species in the mechanisms
regulating embryo implantation, but profound ethical issues prevent systematic study of
human embryo and endometrial interactions in vivo.
To avoid the aforementioned barriers to understanding progesterone sufficiency in
endometrial function, this study group has utilized a modelled cycle, in which progesterone
concentrations are experimentally determined (Figure 3). The controlled cycles are highly
similar to endometrial preparation for an oocyte donor IVF cycle, and thus should result in a
highly receptive endometrium, if physiological progesterone is provided. The protocol
begins with lupron downregulation, followed by transdermal oestrogen replacement at
physiological concentrations, followed by oestrogen plus daily i.m. progesterone at
physiological and subphysiological concentrations, and subsequent biopsy on day 10 of
progesterone treatment. Using this model, endometria from healthy women exposed to
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physiological concentrations of progesterone (40 mg dose, steady-state concentration about
15–25 ng/ml) were compared with those exposed to subphysiological (10 mg dose, steady-
state concentration about 4–6 ng/ml) and assessed histological dating of endometria,
immunohistochemistry for endometrial integrins and quantitative real-time PCR analysis for
nine putative functional markers (Usadi et al. 2008). However, despite a 4-fold difference in
progesterone, none of the assessed markers of endometrial structure and function showed a
significant difference between groups. Given the critical importance of progesterone action
in the endometrium and the expectation of a dose-dependent response, a further reduction in
dose will certainly have effects on both histology and gene expression. However, the data to
date clearly demonstrate that progesterone concentrations in the low end of what is seen in
ovulatory women do not cause profound changes in human endometrial structure or
function. Thus, it would appear that, in normal women, a progesterone dose threshold can be
defined, below which consistent alterations in gene expression and in histological
maturation can be seen. Since this threshold concentration is below the lowest serum
concentrations encountered clinically, the data strongly suggest the following two
conclusions: (i) isolated progesterone deficiency is very unlikely to be a cause of infertility
in couples; and (ii) normal secretory-phase endometrial structure and function in young
healthy women can be achieved across a wide range of progesterone concentrations. It must
be noted that these experiments were performed on young healthy women without any
evidence of endometriosis or infertility.
In all of the above studies, it must also be recognized that local effects of sex steroids can be
strongly influenced by local metabolism. For example, a recent study examined oestrogen
metabolizing enzyme concentrations in human endometrial tissue as well as serum and
tissue oestradiol and oestrone concentrations (Huhtinen et al. 2012). These studies showed
marked differences between serum and tissue oestradiol/oestrone ratios, which depended on
cycle phase and correlated with the type of 17 -hydroxysteroid dehydrogenase expressed.
Progesterone and endometriosis
Abnormalities in endometrial oestrogen and progesterone action
It has been postulated that women with endometriosis-related infertility may be partially
resistant to progesterone actions on the endometrium (Burney et al. 2007; Bulun, Cheng et
al. 2010; Fazleabas 2010). Strikingly, the baboon model demonstrates that simply inducing
peritoneal lesions can result in changes in progesterone action, consistent with progesterone
resistance (Fazleabas, 2010). It is presumed that local inflammation is involved in the
observed alterations in progesterone action, although the mechanism for this remains
unclear. This hypothesis could explain why some women have persistently delayed
histological maturation or persistently abnormal expression of progesterone-regulated genes.
If progesterone resistance is truly present in some women, then, depending on the
mechanism conferring resistance, such women might achieve normal secretory-phase
structure and function with a higher progesterone dose or with treatments targeted at
abnormal inflammation.
Given the known mechanisms of progesterone action, resistance might occur through a
variety of means. Abnormal expression of specific progesterone receptors is one possible
mechanism and women with endometriosis often show failure of mid-secretory
downregulation of epithelial progesterone receptor (Lessey, Killam et al. 1988) and evidence
for specific suppression of progesterone receptor B, but not progesterone receptor A, at
multiple cycle phases (Attia et al. 2000). Another possible mechanism of resistance is an
alteration of expression or function of progesterone receptor chaperones and co-chaperones.
Overexpression of co-chaperone FKBP51 (Hubler et al. 2003) or lack of co-chaperone
FKBP52 (Tranguch et al. 2005; Tranguch et al. 2006; Tranguch et al. 2007) causes
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progesterone resistance in experimental models. Interestingly, high FKBP51 expression
appears to be responsible for the relative progesterone resistance seen in normal squirrel
monkeys (Hubler, Denny et al. 2003); however it also leads to glucocorticoid and androgen
resistance, which has not been described in women with endometriosis. FKBP52 gene
knockout in mice leads to progesterone resistance and embryo implantation failure, which
can be overcome with supplemental progesterone (Tranguch, Wang et al. 2007).
Co-regulators, which bind steroid receptors and modify their nuclear effects, are also
potential modifiers of progesterone resistance. One co-activator, Hic-5, has recently been
shown to be deficient in the stroma of proliferative and late-secretory endometria of women
with endometriosis (Aghajanova et al. 2009), and null mutations in the progesterone
receptor co-activator, steroid receptor co-activator 2 (SRC-2) cause mice to have severe
defects in endometrial receptivity. KLF9 is another progesterone receptor co-regulator,
whose absence in the mouse results in partial progesterone resistance, subfertility and
reduced HOXA10 expression (Simmen and Simmen 2002; Simmen et al. 2002; Zhang et al.
2003). KLF9 was recently shown to be reduced in a mouse model of endometriosis (Lee et
al. 2009) and in infertile women with endometriosis (Pabona et al. 2012). Whether these
findings are a root cause or an effect of endometriosis remains to be evaluated, but they lend
further credence to the concept of progesterone resistance.
Summary and conclusions
To summarize, although a plethora of hormones are produced by the corpus luteum, the
sequential actions of oestrogen and progesterone, without any other corpus luteum
hormones, are sufficient to drive a highly receptive endometrium in humans. The
mechanisms by which oestrogen and progesterone act are highly complex and involve
multiple nuclear receptors as well as recently described membrane receptors. Cell-type
specific effects of oestrogen and progesterone depend on differential expression of
receptors, chaperones and co-regulators as well as chromatin structure. The role of oestrogen
in endometrial proliferation and the importance of that proliferation in embryo implantation
are clear. It is also likely that a small amount of oestrogen is necessary for normal luteal-
phase endometrium in humans, but the sources of oestrogenic activity and dose requirements
remain unclear and the possibility remains that oestrogen or oestrogen-like substances are
made locally within the endometrium.
Progesterone is absolutely necessary, during the secretory phase, to allow the endometrium
to be receptive to the implanting embryo. However, evidence in normal women suggests that
only a very small amount of progesterone is necessary, a concentration achieved by the vast
majority or perhaps all ovulatory women. Thus, in women with otherwise normal
endometrial function, only small amounts of oestrogen and progesterone appear to be
required in the luteal phase for full reproductive function. There is also evidence that some
women, especially those with endometriosis-related infertility, may be somewhat resistant to
the actions of progesterone and it seems that some of these defects are likely to be overcome
with higher concentrations of progesterone, but that hypothesis remains to be proven.
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Classical actions of nuclear oestrogen and progesterone receptors. (a) Steroid receptors bind
steroid and then bind cognate DNA sequences. (b) Non-steroidal ligands can also act
through nuclear steroid receptors. co = co-regulator; HRE = hormone response element; n =
nuclear steroid receptor monomer; ns = non-steroid; p = RNA polymerase; s = steroid.
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Non-classical actions of nuclear oestrogen and progesterone receptors. (a) Membrane-
associated steroid receptors, either isoforms of classical receptors, or (b) unrelated
transmembrane receptors recognize steroid hormones and initiate a cytoplasmic signalling
cascade. (c) Growth factors signalling can act by causing post-translational modifications of
nuclear steroid receptors. (d) Additionally, oestrogen and progesterone can modulate
expression by altering mRNA turnover and translation. (e) Alternatively, steroids can bind
classical nuclear receptors, which act by binding other proteins rather than DNA. co = co-
regulator; G = growth factor; HRE = hormone response element; n = nuclear steroid receptor
monomer; ns = non-steroid; p = RNA polymerase; s = steroid; TF = transcription factor.
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Protocol for modelled cycles (adapted from Usadi et al. 2008).
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Cyclic steroid receptor expression in the human endometrium.
Compartment Phase
Proliferative Early secretory Mid-secretory Late secretory
Epithelium
 Oestrogen receptor α ++++ ++ − −
 Oestrogen receptor β ++ ++ ++ ++
 Progesterone receptor A +++ ++ − −
 Progesterone receptor B +++ ++ + −
Stroma
 Oestrogen receptor α +++ ++ − or + −
 Oestrogen receptor β ++ + + +
 Progesterone receptor A ++ ++ ++ ++
 Progesterone receptor B ++ ++ + −
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